Protara Therapeutics Inc 美股招股说明书（2026年2月2日版）

21,686,760 shares of Common Stock Unless otherwise stated, all references in this prospectus supplement to “we,” “us,” “our,” “Protara,” the “Company” andsimilar designations refer to Protara Therapeutics, Inc. This prospectus supplement updates the prospectus dated May 9, 2024, relating to the resale, from time to time, by the sellingstockholders identified in the prospectus, or, the selling stockholders of up to 21,686,760 shares of our common stock, par value$0.001 per share, (“common stock”) consisting of (i) 9,143,380 shares of common stock held by the selling stockholders (“InitialShares”), (ii) 1,700,000 shares of common stock (“Pre-Funded Warrant Shares”) issuable upon the exercise of pre-funded warrants Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertaintiesdescribed under the heading “Risk Factors” on page 8 of the accompanying prospectus and any similar section contained in NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSIONHASAPPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS The date of this prospectus supplement is January 30, 2026. SELLING STOCKHOLDERS The following information supplements the information set forth under the caption “Selling Stockholders” in the accompanyingprospectus. This prospectus supplement includes information with respect to selling stockholders not previously listed in the The following table sets forth information, as of January 30, 2026, with respect to the selling stockholder named below, regarding thenumber of shares of common stock acquired, or acquirable, by such selling stockholder as a result of an assignment on January 28,2026 by OTA Trading Fund 1 LLC to Funicular Funds, LP of Common Warrants exercisable for up to 142,400 Warrant Shares. Such The number of shares in the column “Number of Shares of Common Stock Owned As of the Date Hereof” represents thenumber of shares of common stock that are actually owned as of the date of this prospectus supplement, and does notrepresent the number of shares that such selling stockholder may otherwise be obligated to report as “beneficially owned” by